LISTEN NOW: In the latest episode of Emerging Experts, Michael LaPelusa, MD shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers. #GICSM | MD Anderson Cancer Center

targetedonc.com/view/lapelusa-…

Multiple facets of a debate at ‘50th ICON conference’ Hyderabad
Glad to have defended the role of Radiation in Rectal Cancer, in light of recent RT Omission trials
#aighospitals #aigoncology #gios
#gicsm

I’m often asked: “why did you choose to be a GI oncologist?” 🚨THIS is why. Because 5 of the 10 deadliest cancers are GI, 🚨& zero GI cancers enjoy top survival. What could be a clearer call to action? Let’s get after it, team! 💪🏼 #GICSM Thanks Ajay Aggarwal for highlighting this…

Short term results of ACT4 shows better compliance and less toxicity with dose reduction in earlier stage anal cancers. #ESTRO2023 #gicsm

Last date of Abstracts: 5 April 2023 and last date of Registrations:15 April 2023 #GastricCancer #GICSM #ISGIO

Check out Dr. Ibrahim Sahin Ibrahim Halil SAHIN, MD UPMC Hillman Cancer Center discussing Early-Onset CRC: A New Epidemic With Knowns and Unknowns

Full 📽️ on #VuMedi
👇
bit.ly/YOCC

#ColorectalCancer AwarenessMonth University of Pittsburgh
#OncEd #gicsm #OncTwitter #oncology #CRCSM #ColorectalCancer

Check out Dr. Ghassan Abou-Alfa Ghassan Abou-Alfa Memorial Sloan Kettering Cancer Center discussing #GI24 'PROOF 301 Trial - Oral FGFR Inhibitor Infigratinib vs. Gemcitabine + Cisplatin in pts W/ Adv. Cholangiocarcinoma W/ FGFR2 Gene Fusion/Rearrangement'

Full📽️on #VuMedi
👇
bit.ly/PROOF301
#gicsm

ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.
#cancer #gastriccancer #gicsm #oncologist #gastriccancer awareness #cells #nonmelanomaskincancer #stomachcancer #softtissuesarcoma #heal #snware #snwhealth #snware research #SNW

ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.
#cancer #gastriccancer #gicsm #oncologist #gastriccancer awareness #cells #nonmelanomaskincancer #stomachcancer #softtissuesarcoma #heal #snware #snwhealth #snware research #SNW

Successfully completed 4th AIG Hands On workshop with eminent national faculty DR VINEETA GOEL and Dr Sayan Paul!! Scaling heights with academics & research, which is the way to go forward!!
#aighospitals #aigoncology #gicsm #gioncology

~My first visit to GCRI, Ahmedabad as a speaker in HCC symposium~Looking forward to visit the place again 😊 #aigoncology #aighospitals #aigcares #gicsm AIG Hospitals

Pembrolizumab + trastuzumab + chemotherapy led to an improvement in overall survival vs placebo in HER2+ locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, meeting the primary end point of the KEYNOTE-811 trial. #GICSM

targetedonc.com/view/pembroliz…

FOLFIRI plus durvalumab 4-month PFS: 44.7% (90% CI, 32.3%-57.7%)

FOLFIRI plus durvalumab and tremelimumab 4-month PFS: 55.6% (90% CI, 42.3%-68.3%)

#gicsm | Tougeron David

cancernetwork.com/view/folfiri-p…

Atualização Diretrizes ASCO 2024: Tratamento Sistêmico para Carcinoma Hepatocelular Avançado

Confira o texto completo em: ascopubs.org/doi/10.1200/JC…

Veja mais sobre #HCC em: mocbrasil.com

#GIcsm Ricardo Carvalho cayamada ASCO Journal of Clinical Oncology

At #ESMO23 , Yelena Y. Janjigian MD presented final progression-free survival + interim overall survival results of pembrolizumab plus trastuzumab and chemotherapy as first-line therapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. #gicsm Memorial Sloan Kettering Cancer Center

THANK YOU to all who supported the GI Cancer Institute and AGITG #gutsychallenge today! 👣 🥾 All funds going towards vital research and #clinicaltrials for gastrointestinal cancers 💊 🔬 bit.ly/Gut5y2 #AGITG #GICSM

Thrilled to celebrate Deborah Schrag today at #ASCO23 . She will be receiving the ASCO-American Cancer Society Society Cancer Prevention Award for her significant contributions to cancer prevention & control. Tune into her lecture at noon CT: #gicsm Memorial Sloan Kettering Cancer Center ow.ly/Wps650OE8j8

#CedarsSinaiCancer at #GI23 . Dr. Ju Dong Yang Ju Dong Yang is co-author on a prospective clinical trial evaluating the performance of a multi-analyte blood test for early detection of #hepatocellularcarcinoma among at-risk patients with liver #cirrhosis . Cedars-Sinai Academic Medicine #gicsm

David H. Ilson of Memorial Sloan Kettering Cancer Center will talk about the timing of immunotherapy in localized gastroesophageal junction and #gastriccancer today from 3:09 p.m. to 3:21 p.m. CT at #ASCO23 . #gicsm ow.ly/jUEf50OEbNq

We’re looking fwd to learning from an all-star lineup of #KOLs in #gicsm #MedTwitter @HJLenz59 Eileen M O’Reilly Ghassan Abou-Alfa Mark Lewis Pamela Kunz, MD, FASCO Franco Roviello Tanios Bekaii-Saab, MD Vinay Prasad MD MPH + personally curated art tour Dr. Andrew Hendifar 😉 Register now: cedars.cloud-cme.com/gicancercme #CME